GLP-1 Weight Loss Programs: Semaglutide & Tirzepatide
More than 40% of American adults are living with obesity [1]. If you are one of them, you already know that calorie counting and exercise programs have not worked the way they were supposed to. That is not a failure of effort. Research published by the National Institutes of Health shows that your body actively fights sustained weight loss through a process called metabolic adaptation, reducing the number of calories you burn and increasing hunger signals the longer you restrict food intake [2][3]. You are not losing a battle of willpower. You are fighting your own biology.
GLP-1 receptor agonists (specifically Semaglutide and Tirzepatide) are prescription medications that work by targeting the biological mechanisms behind appetite and weight regulation. In large-scale clinical trials published in the New England Journal of Medicine, these medications produced average weight reductions of 14.9% to 22.5% of body weight over 68 to 72 weeks [4][5]. They are not supplements, not diet pills, and not a shortcut. They are prescription therapies that a licensed provider evaluates, prescribes, and monitors as part of a broader treatment plan.
Transformation Health offers compounded formulations of these medications as part of an all-inclusive program that includes provider care, lab work, coaching, and free shipping, starting at $199/mo. Compounded medications are not FDA-approved and have not been independently evaluated by the FDA for safety, efficacy, or quality. They differ from commercially available branded medications.
How GLP-1 Medications Work
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after eating. It plays a central role in how your brain regulates hunger, how quickly food moves through your stomach, and how your body manages blood sugar [6]. In people with obesity, these signaling pathways often do not function as they should. Think of it like a thermostat that has stopped reading the room temperature correctly: your brain keeps telling you to eat even when your body has plenty of stored energy.
GLP-1 medications amplify the natural effects of this hormone through three complementary mechanisms:
Appetite regulation
GLP-1 medications act on receptors in brain regions involved in appetite control, reducing hunger and what researchers describe as "food cue reactivity," the constant mental preoccupation with eating that patients often call "food noise" [7]. Many patients notice reduced food preoccupation within the first week or two of treatment.
Slowed gastric emptying
These medications slow how quickly food leaves your stomach, helping you feel full longer after meals [6]. You eat less because you genuinely feel satisfied, not because you are fighting cravings. This effect is one reason patients report being comfortable with smaller portions without the constant sense of deprivation that comes with traditional calorie restriction.
Metabolic regulation
GLP-1 medications regulate insulin secretion and blood sugar levels, supporting metabolic health more broadly [6]. This is especially relevant for patients with insulin resistance, prediabetes, or type 2 diabetes. The SELECT trial (published in NEJM, 2023) also demonstrated a 20% reduction in major cardiovascular events in patients with obesity taking semaglutide [8].
Why this matters for women in perimenopause
If you are a woman between 35 and 55, the weight gain you have experienced over the past several years is likely not just about diet or activity level. Research shows that estrogen decline during the menopausal transition shifts where your body stores fat (from hips and thighs to the abdomen) and disrupts the appetite-regulating signals that GLP-1 medications target [9][10]. According to a review published in Climacteric, roughly 68% of women ages 40-59 are classified as overweight or obese, and the rate of weight gain accelerates during perimenopause regardless of changes in diet or exercise [11]. GLP-1 medications address both the appetite dysregulation and the metabolic shifts that make this stage of life so frustrating for weight management.
See If You Qualify in Under 5 Minutes
Our free online assessment is reviewed by a U.S.-licensed provider. No insurance needed. No commitment required.
Get StartedSemaglutide vs. Tirzepatide: Understanding Your Options
We offer two primary active ingredients, each with distinct clinical profiles. Your provider will recommend the option they determine is clinically appropriate based on your health profile, but understanding the differences helps you feel informed about your treatment plan.
Semaglutide is a GLP-1 receptor agonist. In the STEP 1 trial (1,961 participants, published in the New England Journal of Medicine), patients receiving semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. More than 86% of participants achieved at least 5% weight loss, and over 50% achieved 15% or more [4].
Tirzepatide is a dual GLP-1/GIP receptor agonist, meaning it targets two hormonal pathways rather than one. In the SURMOUNT-1 trial (2,539 participants, also published in NEJM), participants receiving tirzepatide achieved average weight reductions of 16.0% (5 mg dose), 21.4% (10 mg dose), and 22.5% (15 mg dose) over 72 weeks [5]. The FDA approved tirzepatide (as Zepbound) for chronic weight management in November 2023 [12].
These results reflect the FDA-approved branded formulations studied under controlled trial conditions. Our compounded formulations contain the same active ingredients but have not been independently evaluated by the FDA for safety, efficacy, or quality, and may differ in formulation, purity, and potency.
Microdose GLP-1/GIP
Maintenance & support
$199/mo
Oral or injectable
- Tirzepatide, NAD+, B12
- Maintenance support
- Clinical team access
- BMI 20+ eligible
- Free shipping
GLP-1 (Semaglutide)
Injectable or Oral
$249/mo injectable
$279/mo oral
- Reduces food noise
- Increases fullness
- Personalized coaching
- Provider care & labs included
- Free shipping
GLP-1/GIP (Tirzepatide)
Dual-action metabolic formula
$339/mo
Oral or injectable
- Dual-action GLP-1/GIP
- Comprehensive health coaching
- Provider care & labs included
- Free shipping
- Cancel anytime
For a detailed side-by-side comparison of all three programs, visit our medication comparison page.
Who Is a Good Candidate for GLP-1 Treatment?
GLP-1 medications are not appropriate for everyone. Our U.S.-licensed providers evaluate each patient’s health history, current medications, and goals to determine whether treatment is clinically appropriate. Not sure if you are a candidate? See our full eligibility criteria and assessment process.
The American Medical Association recognized obesity as a chronic disease in 2013, and the National Institutes of Health identifies a BMI of 30 or higher as the clinical threshold for obesity [13]. If your BMI is 27 or higher (or 25+ with a condition like type 2 diabetes, hypertension, or sleep apnea), you may be eligible for evaluation. The decision to prescribe is always made by your provider based on your complete health picture.
What makes our program different
Every patient receives individualized care from a board-certified, U.S.-licensed provider. Your treatment plan is tailored to your health profile, not a one-size-fits-all protocol. Beyond medication, you receive:
- Personalized nutrition guidance based on your dietary needs and goals
- Exercise recommendations appropriate for your fitness level, with emphasis on resistance training to preserve lean muscle mass [14]
- Lifestyle coaching for sustainable habit changes
- 24/7 message support from your clinical care team
- Comprehensive lab work through Quest or Labcorp, included at no extra cost
Your plan covers everything in one locked-in monthly price: medication, provider care, labs, coaching, and free shipping. No hidden fees, no surprise charges, no insurance paperwork required.
What to Expect During GLP-1 Treatment
Understanding the timeline helps set realistic expectations. Individual experiences vary, and your provider will track your progress and adjust your plan as needed. For a comprehensive week-by-week guide, visit our patient guide.
Weeks 1-2: Getting started
GLP-1 medications start at a low dose and gradually increase (a process called titration). Most patients notice mild appetite changes and reduced "food noise" within the first week [7]. Some experience mild nausea, which is the most commonly reported side effect in clinical trials and typically improves within a few days [4]. Your care team is available 24/7 if you have questions about side effects or dosing.
Weeks 2-8: Building habits
As your dose increases, appetite regulation becomes more pronounced. This is when healthy eating habits start to take hold because the biological barrier (constant hunger signaling) is reduced. Your provider may recommend focusing on protein intake (research from the Endocrine Society suggests 1.2 to 1.6 grams per kilogram of body weight daily to help preserve lean muscle mass during weight loss [14][15]), adequate hydration, and gentle exercise.
Months 2-6: Continued progress
With continued treatment and lifestyle changes, many patients see their most noticeable progress during this phase. In the STEP 1 trial, the majority of weight loss occurred in the first 6-8 months of treatment [4]. Your provider monitors your response through regular check-ins and lab work, adjusting your dose as needed.
Months 6-12+: Long-term management
Patients who stay consistent with medication, nutrition, and exercise may continue to see improvements in weight and metabolic markers over time. Your provider may recommend transitioning to the Microdose maintenance program ($199/mo) for long-term weight management at a lower dose and cost. The goal is to build habits that outlast the medication.
Ready to Get Started?
Complete our free 5-minute assessment. A licensed provider will review your profile and determine if a GLP-1 program is clinically appropriate for you.
Get StartedThe Biology Behind Weight Regain (and Why Medication Helps)
If you have lost weight before and gained it back, it is worth understanding why. Research from the National Institutes of Health demonstrates that when you lose weight through calorie restriction alone, your body lowers its resting metabolic rate by more than what would be expected from the weight loss itself [2]. A landmark NIH study of Biggest Loser contestants found that this metabolic adaptation persisted for at least six years after the competition, with participants burning an average of 499 fewer calories per day than expected for their body size [3].
At the same time, levels of leptin (the hormone that signals fullness) drop, while ghrelin (the hormone that signals hunger) increases [2]. Your body is essentially working against you, demanding more food while burning less energy. This is not a failure of discipline. It is a well-documented survival mechanism.
GLP-1 medications address this cycle directly. By reducing appetite signaling at the brain level and slowing gastric emptying, they create the conditions for sustained calorie reduction without the compensatory hunger surge that derails most diet-only approaches [6][7]. Combined with nutrition guidance, exercise, and medical monitoring, this is what a medically supervised weight loss program looks like.
The Getting-Started Process
Getting evaluated for a GLP-1 prescription through Transformation Health is entirely online. No office visits, no waiting rooms, no insurance paperwork. The complete process, from assessment to medication delivery, typically takes 5-7 business days.
1. Online assessment
Share your health history, current medications, and weight management goals in about 5 minutes.
2. Provider review
A U.S.-licensed provider evaluates your profile and determines if treatment is clinically appropriate for you.
3. Medication delivered
If prescribed, your medication ships from a licensed US-based pharmacy with free, discreet shipping.
For residents of AR, DC, DE, MS, NM, RI, and WV, state regulations require an initial video consultation before a prescription can be written. Learn more at our get prescription page.
Pricing and What’s Included
All of our programs are all-inclusive: your monthly price covers medication, provider care, lab work (through Quest or Labcorp), coaching, and shipping. No hidden fees, no insurance required. For complete pricing details, visit our cost and pricing page.
| Program | Price | Often Considered For |
|---|---|---|
| GLP-1 Semaglutide (Injectable) | $249/mo | First-time GLP-1 patients |
| GLP-1 Semaglutide (Oral) | $279/mo | Patients who prefer oral medication |
| GLP-1/GIP Tirzepatide | $339/mo | Patients whose provider recommends dual-receptor treatment |
| Microdose GLP-1/GIP | $199/mo | Weight maintenance, BMI 20+ |
Brand-name GLP-1 medications typically cost $1,000-$1,500+/mo without insurance [6]. Our compounded programs start at $199/mo. Compounded medications are different products from brand-name drugs. They are prepared by licensed US-based pharmacies and are not FDA-approved. Read our full cost and pricing breakdown for a detailed comparison.
Citations
- CDC National Center for Health Statistics. “Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023.” NCHS Data Brief No. 508, September 2024. https://www.cdc.gov/nchs/products/databriefs/db508.htm
- Muller MJ, Bosy-Westphal A. “Adaptive thermogenesis with weight loss in humans.” Obesity. 2013;21(2):218-228. https://pmc.ncbi.nlm.nih.gov/articles/PMC3673773/
- Fothergill E, et al. “Persistent metabolic adaptation 6 years after The Biggest Loser competition.” Obesity. 2016;24(8):1612-1619. https://pmc.ncbi.nlm.nih.gov/articles/PMC4989512/
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Prescription Medications to Treat Overweight and Obesity.” https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
- Dalton B, et al. “What Is Food Noise? A Conceptual Model of Food Cue Reactivity.” Nutrients. 2023;15(22):4809. https://pmc.ncbi.nlm.nih.gov/articles/PMC10674813/
- Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
- Greendale GA, et al. “Changes in body composition and weight during the menopause transition.” JCI Insight. 2019;4(5):e124865. https://pmc.ncbi.nlm.nih.gov/articles/PMC8569454/
- Kapoor E, et al. “Weight Gain in Women at Midlife: A Concise Review of the Pathophysiology and Strategies for Management.” Mayo Clinic Proceedings. 2017;92(10):1552-1558. https://pmc.ncbi.nlm.nih.gov/articles/PMC8373626/
- Davis SR, et al. “Understanding weight gain at menopause.” Climacteric. 2012;15(5):419-429. https://pubmed.ncbi.nlm.nih.gov/22978257/
- U.S. Food and Drug Administration. “FDA Approves New Medication for Chronic Weight Management.” November 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Treatment for Overweight and Obesity.” https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/treatment
- Endocrine Society. “Consuming more protein may protect patients taking anti-obesity drug from muscle loss.” ENDO 2025 Press Release. https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/haines-press-release
- Neeland IJ, et al. “Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.” Diabetes, Obesity and Metabolism. 2024;26(5):1732-1750. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15728